Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the worst-performing stocks on Tuesday. Vertex Pharmaceuticals nosedived ...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Vertex Pharmaceuticals (NASDAQ:VRTX) shares plunged on Tuesday despite the company posting second quarter revenue and adjusted profit above expectations. The stock is down 17% in early trade after the ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here’s what to ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) continued to drop in the premarket on Tuesday after the Swiss biotech posted lower-than-expected Q2 2025 financials, as investors focused on sales from its ...

Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...